S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The 3-Stock Retirement Blueprint (Ad)
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
The 3-Stock Retirement Blueprint (Ad)
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The 3-Stock Retirement Blueprint (Ad)
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
The 3-Stock Retirement Blueprint (Ad)
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The 3-Stock Retirement Blueprint (Ad)
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
The 3-Stock Retirement Blueprint (Ad)
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The 3-Stock Retirement Blueprint (Ad)
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
The 3-Stock Retirement Blueprint (Ad)
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
NASDAQ:BMRA

Biomerica - BMRA Stock Forecast, Price & News

$3.93
-0.05 (-1.26%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.64
$4.01
50-Day Range
$2.64
$3.98
52-Week Range
$2.56
$7.38
Volume
52,195 shs
Average Volume
61,511 shs
Market Capitalization
$52.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.00

Biomerica MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
100.0% Downside
$0.00 Price Target
Short Interest
Healthy
2.90% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.95mentions of Biomerica in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.61 out of 5 stars

Medical Sector

411th out of 1,093 stocks

Diagnostic Substances Industry

9th out of 17 stocks

BMRA stock logo

About Biomerica (NASDAQ:BMRA) Stock

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

Receive BMRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biomerica and its competitors with MarketBeat's FREE daily newsletter.

BMRA Stock News Headlines

Biomerica Reports Fiscal 2022 Year End Results
Biomerica (BMRA) Investor Presentation - Slideshow
See More Headlines
Receive BMRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biomerica and its competitors with MarketBeat's FREE daily newsletter.

BMRA Company Calendar

Last Earnings
1/13/2022
Today
10/01/2022
Next Earnings (Estimated)
10/13/2022
Fiscal Year End
5/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BMRA
Employees
66
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$0.00
High Stock Price Forecast
$0.00
Low Stock Price Forecast
$10,000,000.00
Forecasted Upside/Downside
+230.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-4,530,000.00
Pretax Margin
-23.88%

Debt

Sales & Book Value

Annual Sales
$18.87 million
Book Value
$0.65 per share

Miscellaneous

Free Float
10,233,000
Market Cap
$52.70 million
Optionable
Not Optionable
Beta
-0.44

Key Executives

  • Mr. Zackary S. Irani (Age 56)
    Chairman & CEO
    Comp: $136.61k
  • Mr. Allen C. Barbieri (Age 64)
    Exec. Vice-Chairman & Corp. Sec.
    Comp: $90k
  • Mr. Steven Sloan (Age 52)
    CFO & Treasurer
    Comp: $166.67k
  • Ms. Lucy Liu Ph.D.
    Director of Manufacturing & Technical Operations
  • Hans Boehringer
    Sr. VP of POC R&D













BMRA Stock - Frequently Asked Questions

Should I buy or sell Biomerica stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biomerica in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BMRA shares.
View BMRA analyst ratings
or view top-rated stocks.

What is Biomerica's stock price forecast for 2022?

1 brokerages have issued twelve-month target prices for Biomerica's shares. Their BMRA share price forecasts range from $10,000,000.00 to $0.00. On average, they anticipate the company's stock price to reach $0.00 in the next year. This suggests that the stock has a possible downside of 100.0%.
View analysts price targets for BMRA
or view top-rated stocks among Wall Street analysts.

How have BMRA shares performed in 2022?

Biomerica's stock was trading at $3.89 on January 1st, 2022. Since then, BMRA stock has increased by 1.0% and is now trading at $3.93.
View the best growth stocks for 2022 here
.

When is Biomerica's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 13th 2022.
View our BMRA earnings forecast
.

How were Biomerica's earnings last quarter?

Biomerica, Inc. (NASDAQ:BMRA) posted its quarterly earnings data on Thursday, January, 13th. The company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by $0.01. The company earned $4.65 million during the quarter. Biomerica had a negative net margin of 24.01% and a negative trailing twelve-month return on equity of 50.64%.

What other stocks do shareholders of Biomerica own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biomerica investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Johnson & Johnson (JNJ), Ampio Pharmaceuticals (AMPE), OPKO Health (OPK), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), Co-Diagnostics (CODX), FuelCell Energy (FCEL) and Trevena (TRVN).

What is Biomerica's stock symbol?

Biomerica trades on the NASDAQ under the ticker symbol "BMRA."

How do I buy shares of Biomerica?

Shares of BMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biomerica's stock price today?

One share of BMRA stock can currently be purchased for approximately $3.93.

How much money does Biomerica make?

Biomerica (NASDAQ:BMRA) has a market capitalization of $52.70 million and generates $18.87 million in revenue each year. The company earns $-4,530,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis.

How can I contact Biomerica?

Biomerica's mailing address is 17571 Von Karman Avenue, Irvine CA, 92614. The official website for the company is www.biomerica.com. The company can be reached via phone at (949) 645-2111, via email at jnesbett@institutionalms.com, or via fax at 949-553-1231.

This page (NASDAQ:BMRA) was last updated on 10/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.